Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INS1033 in Healthy Participants
NCT07765706Phase 1Recruiting
- Sponsor
- Insmed Incorporated
- Start
- Aug 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of INS1033 (2 arms), sponsored by Insmed Incorporated. Primary endpoint: Number of Participants Who Experienced at-Least One Adverse Event at 21 days. Started Aug 2026; status: recruiting.
02
Drugs
INS1033
Beyond the preview
Go deeper on NCT07765706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07765706.